Roche's Alecensa has been recommended for routine NHS use as an adjuvant treatment for ALK-positive non-small cell lung cancer (NSCLC), the first targeted therapy for this indication. Alecensa ...

Alecensa is used to treat non-small-cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive. Some types of lung cancer can be treated with a drug that works when it is combined ...

The first patient has been dosed in the phase 3 TACTI-004 trial evaluating efti with Keytruda and chemotherapy for advanced ...

The Food and Drug Administration (FDA) has only approved ceritinib (Zykadia) and lorlatinib (Lorbrena) to treat ALK-positive lung cancer. However, a doctor may still prescribe if you have ROS1 ...

First patient safely dosed at Calvary Mater Newcastle Hospital in Australia, marking a significant milestone for ImmutepGlobal Phase III with ...

Targeted therapies have significantly improved outcomes for patients with non-small cell lung cancer (NSCLC) with actionable mutations. However, many tumors inevitably develop drug resistance and ...

An application was submitted to the European Medicines Agency seeking approval for treatment with sugemalimab in stage 3 ...

Immutep (ASX:IMM) has dosed the first patient in its pivotal Phase III trial evaluating eftilagimod alfa (efti) for the ...

Despite the high incidence of brain metastasis after resection of non-small cell lung cancer (NSCLC), the National Comprehensive Cancer Network guidelines do not recommend central nervous system (CNS) ...